New England Research Institutes Assists Medtronic, Inc. in Obtaining FDA Approval of the TalentTM Abdominal Stent Graft

WATERTOWN, Mass.--(BUSINESS WIRE)--New England Research Institutes, Inc. (NERI), a global, privately held specialty Contract Research Organization (CRO), today announced that their statistical analysis of data in The Lifeline Registry of Endovascular Aneurysm Repair (EVAR) contributed to the recent FDA approval of Medtronic, Inc.’s TalentTM Abdominal Stent Graft. NERI’s assessment of the outcomes in the treatment of abdominal aortic aneurysms (AAA) demonstrated that the TalentTM Abdominal Stent Graft’s primary safety endpoints were statistically superior compared to open surgery.